

Supporting Information

for

Zn-mediated electrochemical α -alkylation of amines with halogenated alkanes through convergent paired electrolysis

Xiaoyu Zhan,^a Hongyu Liu,^a Rui Liu,^a Yanmin Huang*^b and Yungui Peng*^a

^a Key Laboratory of Applied Chemistry of Chongqing Municipality, School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China. E-mail: pengyungui@hotmail.com, pyg@swu.edu.cn.

^b College of Chemistry and Life Science, Guangxi Teachers Education University, Nanning 530001, China. E-mail: huangyanmin828@gxtc.edu.com.

Table of Contents

1. General information.....	2
2. Structures of starting materials.....	2
3. Synthetic routes for 1,2,3,4-tetrahydroisoquinolines.....	3
4. Synthetic routes for benzyl bromide	3
5. General procedure of alkylation reaction	4
6. Procedure for gram scale alkylation reaction.....	5
7. Formal synthesis of the 8-oxoprotoberberine derivative 55.....	5
8. Synthetic routes for benzyl bromide	6
9. Procedure for control experiments	6
10. HRMS data of Iminium ion 58	9
11. Cyclic voltammetric experiments	10
12. Characterization data for products.....	11
13. References	25
14. The spectra of NMR.....	26


1. General information

All reagents and solvents were purchased from Adamas Reagent, Chendu Huaxia Chemical Reagent, Energy chemical, Alfa Aesa chemical company, Aladin Industrial Crporation, Macklin Biochemical Company, Acros Organics, Bide Pharmatech Ltd, and so forth. All chemicals are without purified unless otherwise stated. Petroleum ether (PE) and ethyl acetate (EA) for flash column chromatography were distilled before use. Thin layer chromatography (TLC) for analysis was performed on Schleicher & Schuell F1400/LS 254 silica gel plates, and observation under UV light ($\lambda = 254$ nm). ^1H NMR spectra recorded at 600 MHz, and ^{13}C NMR were recorded at 151 MHz. Use CDCl_3 as solvent and tetramethyl silane as internal standard (0.00 ppm) unless otherwise stated. High resolution mass spectra were recorded using Q-TOF time-of-flight mass spectrometer. Coupling constants (J) were reported in Hertz (Hz). Flash chromatography was performed with Qingdao Haiyang flash silica gel (300–400 mesh). The substrates amine could be prepared according to literature.^{1,2} Benzyl bromide could be easily prepared according to literature.³


Abbreviated as follows: s (singlet); d (doublet); t (triplet); q (quartet); m (multiplet); THF (Tetrahydrofuran); DMF (Dimethylformamide); SDS (Sodium dodecyl sulfonate); FE (Faraday efficiency).


2. Structures of starting materials

2.1 Various amines used in this reaction




2.1 Various haloalkanes used in this reaction





3. Synthetic routes for 1,2,3,4-tetrahydroisoquinolines^{1,2}



To a solution of phenylacetic acid (**M1**, 20 mmol, 1.0 equiv.) in THF (50 mL), $\text{BH}_3\cdot\text{DMS}$ (8 mL, 100 mmol, 5 equiv.) was added dropwise at room temperature. The solution was refluxed for 1 h and then cooled to room temperature. The reaction was quenched by adding MeOH (40 mL) dropwise. The mixture was concentrated, and the resulting residue was purified by silica gel chromatography to give alcohol **M2** as oil.


LiBr (1 g, 10 mmol, 0.5 equiv.) was added to a solution of phenylethyl alcohol (**M2**, 20 mmol, 1.0 equiv.) in dimethoxymethane (40 mL, 400 mol, 20 equiv.). In the catalysis of a spatula tip of *p*-TsOH, the reaction mixture was refluxed for 1 day. The reaction mixture was cooled to room temperature and concentrated. Then the resulted crude residue was purified by silica gel chromatography to give compound **M3**.

TMSOTf (0.35 mL, 1.95 mmol, 0.25 equiv.) was added drop wise to the solution of compound **M3** (10 mmol, 1.0 equiv.) in MeCN (40 mL) at 0 °C. The reaction mixture was warmed to room temperature, stirred for an additional 10 h, and then quenched by addition of saturated NaHCO_3 (15 mL). The MeCN was removed under reduced pressure, and the resulting aqueous layer was extracted with Et_2O (3 x 20 mL). Combined the ethereal layers and dried with Na_2SO_4 , filtered, and concentrated to give the crude products, then, purified by silica gel chromatography furnished compound **M4**.

A mixture of **M4** (10 mol, 1.0 equiv.) and 33% HBr in AcOH (10 mL) was heated in a sealed tube at 110 °C for 18 h. After cooling to rt, and then poured into water (100 mL) and extracted with diethyl ether (3 x 100 mL). The organic phase was washed with 1 M NaOH (200 mL) and brine (100 mL), dried (MgSO_4) and evaporated *in vacuo*. The residue was purified by silica gel chromatography to give compound **M5**.

To a solution of **M5** (10 mmol, 1.0 equiv.) in CH_3CN (50 mL) was added aniline (10.0 mmol, 1.0 equiv.) and K_2CO_3 (20 mmol, 2.0 equiv.). The solution was refluxed for 5 h and then cooled to room temperature. The MeCN was removed under reduced pressure, and the resulting mixture was poured into water (100 mL) and extracted with diethyl ether (3 x 100 mL). The ethereal layer was dried (Na_2SO_4), filtered, and concentrated to give the crude products. The crude products were purified by silica gel chromatography to give compound **M6**.

4. Synthetic routes for benzyl bromide



A solution of benzaldehyde (**M7**, 20 mmol, 1.0 equiv.) in MeOH (50 mL), NaBH₄ (750 mg, 30 mmol, 1.5 equiv.) was added at 0 °C. The reaction mixture was stirred at 0 °C for 1 h, and then MeOH was removed under reduced pressure, the resulting mixture was poured into water (100 mL) and extracted with diethyl ether (3 × 100 mL). The ethereal layer was dried (Na₂SO₄), filtered, and concentrated to give the crude products. The crude products were purified by silica gel chromatography to give compound **M8**.

A solution of benzyl alcohol **M8** in DCM (20 mL), PBr₃ (1.8 mL, 5.4 g, 30 mmol, 1.5 equiv.) was added at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h. The reaction was quenched by adding water (10 mL) dropwise. Then the mixture was poured into water (100 mL) and extracted with diethyl ether (3 × 100 mL). The ethereal layer was dried (Na₂SO₄), filtered, and concentrated to give the crude products. The crude products were purified by silica gel chromatography to give compound **M9**.

5. General procedure of alkylation reaction

5.1 General procedure A of alkylation reaction

An undivided cell was equipped with a magnet stirrer, carbon rod as anode and zinc rod as cathode. The substrate amine (0.3 mmol), haloalkane (0.9 mmol), ZnCl₂ (0.6 mmol), ⁿBu₄Ni (0.3 mmol) was added to the cosolvent DMF (1.5 mL) and THF (1.5 mL). The resulting mixture was allowed to stir and electrolyze at constant current conditions (15 mA) at room temperature for 1.7 h. After the reaction is complete, triethylamine (3 mL) was added to quench the reaction. Then the reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic phase was concentrated in vacuo. The residue was purified by column chromatography on silica gel or aluminum oxide to afford the desired product.

5.2 General procedure B of alkylation reaction

An undivided cell was equipped with a magnet stirrer, carbon rod as anode and zinc rod as cathode. The substrate amine (0.3 mmol), haloalkane (0.9 mmol), ZnCl₂ (0.6 mmol), NH₄I (0.3 mmol) and sodium dodecyl sulfonate (SDS, 20 mol%) was added to the cosolvent THF (2.7 mL) and H₂O (0.3 mL). The resulting mixture was allowed to stir and electrolyze at constant current conditions (15 mA) at room temperature for 2 h. After the reaction is complete, triethylamine (3 mL) was added to quench the reaction. Then the reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic phase was concentrated in vacuo. The residue was purified by column chromatography on silica gel or aluminum oxide to afford the desired product.

5.3 General procedure C of alkylation reaction


An undivided cell was equipped with a magnet stirrer, carbon rod as anode and zinc rod as cathode. The substrate amine (0.3 mmol), haloalkane (1 mmol), ZnCl₂ (0.6 mmol), NH₄I (0.3 mmol) and Na₂SO₃ (0.75 mmol) was added to the cosolvent DMF (1.5 mL), THF (1.5 mL) and H₂O (0.3 mL). The resulting mixture was allowed to stir and electrolyze at constant current conditions (15 mA) at room temperature for 4 hours. After the reaction is complete, triethylamine (3 mL) was added to quench the reaction. Then the reaction mixture was poured into water (50 mL) and then extracted with ethyl acetate (3 × 15 mL). The combined organic phase was concentrated in

vacuo. The residue was purified by column chromatography on silica gel or aluminum oxide to afford the desired product.

6. Procedure for gram scale alkylation reaction




Figure S1. Gram-scale electrolysis setup



An undivided cell was equipped with a magnet stirrer, carbon rod as anode and zinc plate ($8 \times 10 \text{ cm}^2$) as cathode (the electrolysis setup is shown in Fig. S1). The substrate amine (5 mmol), haloalkane (15 mmol), ZnCl_2 (10 mmol), $n\text{Bu}_4\text{NI}$ (5 mmol) was added to the cosolvent DMF (25 mL) and THF (25 mL). The resulting mixture was allowed to stir and electrolyze at constant current conditions (150 mA) at room temperature for 3 h. After the reaction is complete, triethylamine (10 mL) was added to quench the reaction. Then the reaction mixture was poured into water (150 mL) and then extracted with ethyl acetate ($3 \times 30 \text{ mL}$). The combined organic phase was concentrated in vacuo. The residue was purified by column chromatography on silica gel to afford the desired product **17** (1.4 g, 82% yield, FE = 49%).

7. Formal synthesis of the 8-oxoprotuberberine derivative **55**³




Step I: An undivided cell was equipped with a magnet stirrer; carbon rod as anode and zinc rod as cathode. The substrate amine **52** (0.3 mmol), allyl bromide (0.9 mmol), ZnCl_2 (0.6 mmol), NH_4I (0.3 mmol) and sodium dodecyl sulfonate (SDS, 20 mol%) was added to the cosolvent THF (2.7 mL) and H_2O (0.3 mL). The resulting mixture was allowed to stir and electrolyze at constant current conditions (15 mA) at room temperature for 2 h. After the reaction is complete,

triethylamine (3 mL) was added to quench the reaction. Then the reaction mixture was poured into water (50 mL) and then extracted with ethyl acetate (3 × 15 mL). The combined organic phase was concentrated in vacuo. The residue was purified by column chromatography on silica gel to afford the desired product **53** (52 mg, 50% yield, FE = 26%).


Step II: A solution of amine **53** (0.1 mmol), Pd(OAc)₂ (10 mol%) and PPh₃ (20 mol%), K₂CO₃ (0.2 mmol), in dried CH₃CN (2 mL) at 70 °C under argon atmosphere for 12 h. Then, the reaction mixture was cooled to rt. The solid was removed and washed with ethyl acetate. Combined the organic solution together and the solvent was removed by vacuum to give the crude product, which was purified by flash chromatography on silica gel to provide pure product **54** as light-yellow oil in 45% yield.

8. Synthetic routes for benzyl bromide⁴



In an oven-dried Schlenk tube equipped with a magnetic stir bar the amine (0.5 mmol, 1.0 equivalent.) was dissolved in DMF (1 mL). CBrCl₃ (0.75 mmol, 1.5 equiv.) was added under nitrogen and the tube was then irradiated with blue LEDs for 30 min at room temperature. After the reaction is complete, ethyl acetate was dropped slowly into the mixture of reaction with vigorous stirring. After a few minutes the brown precipitate emerged, filtered and washed three times with ethyl acetate to obtain the brown solid, which is iminium ion **56**.


9. Procedure for control experiments




Iminium ion **56** was prepared according to literature⁴. An undivided cell was equipped with a magnet stirrer, carbon rob as anode and zinc rob as cathode. The substrate haloalkane (0.9 mmol), iminium ion **56** (0.3 mmol), ZnCl₂ (0.6 mmol), ⁿBu₄NI (0.3 mmol) was added to the cosolvent DMF (1.5 mL) and THF (1.5 mL). The resulting mixture was allowed to stir and electrolyze at constant current conditions (15 mA) at room temperature for 1.7 h. After the reaction is complete, triethylamine (3 mL) was added to quench the reaction. Then the reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic phase was concentrated in vacuo. The residue was purified by column chromatography on silica gel to afford the desired product **3** in 77% yield.




Figure S2. Zinc deposition (**Zn-1**) on the front side of zinc plate (left picture) and Zinc deposition (**Zn-2**) on the back side of zinc plate (right picture).




The Iminium ion **56** (0.3 mmol), haloalkane (0.9 mmol), $n\text{Bu}_4\text{NI}$ (0.3 mmol), **Zn-1** (0.3 mmol) or **Zn-2** (0.3 mmol) was added to the cosolvent DMF (1.5 mL) and THF (1.5 mL). The resulting mixture was allowed to stir for 1.7 h. After the reaction is complete, triethylamine (3 mL) was added to quench the reaction. Then the reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3×15 mL). The combined organic phase was concentrated in vacuo. The residue was purified by column chromatography on silica gel to afford the desired product.



An oven-dried Schlenk tube was equipped with a magnet stirrer, the amine **1** (0.3 mmol), ZnCl_2 (0.6 mmol) or not, $n\text{Bu}_4\text{NI}$ (0.3 mmol), I_2 (0.3 mmol) were added to the cosolvent DMF/THF or amine **1** (0.3 mmol), ZnCl_2 (0.6 mmol), NH_4I (0.3 mmol), SDS (0.06 mmol), I_2 (0.3 mmol) were added to the cosolvent THF/ H_2O and stir for a few minutes, then the ZnEt_2 (1 mol/L, 0.9 ml) was added. The resulting mixture was allowed to stir for 1.7 h or 2 h. After the reaction is complete, triethylamine (3 mL) was added to quench the reaction. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3×15 mL). The combined organic phase was concentrated in vacuo. The residue was purified by column chromatography on silica gel to afford the desired product.




An oven-dried Schlenk tube was equipped with a magnet stirrer, the amine **1** (0.3 mmol), ZnCl_2 (0.6 mmol), $n\text{Bu}_4\text{NI}$ (0.3 mmol), I_2 (0.3 mmol) were added to the cosolvent DMF/THF or amine **1** (0.3 mmol), ZnCl_2 (0.6 mmol), NH_4I (0.3 mmol), SDS (0.06 mmol), I_2 (0.3 mmol) were added to the cosolvent THF/ H_2O . The resulting mixture was allowed to stir for 1.7 h or 2h. triethylamine (3 mL) was added to quench the reaction. The Iminium ion **58** was detected by HRMS.

Table S1 Radical capture experiments

entry	radical scavenger	yield
1	TEMPO (2 equiv.)	78%
2	TEMPO (1 equiv.)	76%
3	TEMPO (0.5 equiv.)	78%
4	TEMPO (0.1 equiv.)	75%
5	BHT (2 equiv.)	80%

An undivided cell was equipped with a magnet stirrer, carbon rob as anode and zinc rob as cathode. The substrate haloalkane (0.9 mmol), amine **1** (0.3 mmol), ZnCl₂ (0.6 mmol), ⁿBu₄NI (0.3 mmol) and radical scavenger was added to the cosolvent DMF (1.5 mL) and THF (1.5 mL). The resulting mixture was allowed to stir and electrolyze at constant current conditions (15 mA) at room temperature for 1.7 h. After the reaction is complete, triethylamine (3 mL) was added to quench the reaction. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic phase was concentrated in vacuo. The residue was purified by column chromatography on silica gel to afford the desired product **3** (Table S1).

Table S2 Effect of Zn²⁺ salts on the reaction



entry	Zn ²⁺ salts	Yield ^a	yield ^b
1	ZnBr ₂ (2 equiv.)	76%	56%
2	ZnI ₂ (2 equiv.)	ND	37%
3	Zn(OAc) ₂ (2 equiv.)	30%	race
4	Zn(OTf) ₂ (2 equiv.)	ND	55%
5	ZnCl ₂ (1 equiv.)	38%	--
6	ZnCl ₂ (0.5 equiv.)	20%	--
7	ZnCl ₂ (0.2 equiv.)	14%	--

^a THF (1.5 mL), DMF (1.5 mL), ⁿBu₄NI (1 equiv.)

^b THF (2.7 mL), H₂O (0.3 mL), NH₄I (1 equiv.), SDS (20 mol%)

An undivided cell was equipped with a magnet stirrer, carbon rob as anode and zinc rob as cathode. The substrate haloalkane (0.9 mmol), amine **1** (0.3 mmol), Zn²⁺ salts (0.6 mmol), ⁿBu₄NI or NH₄I (0.3 mmol) was added to the cosolvent DMF/THF or THF/H₂O. The resulting mixture was allowed to stir and electrolyze at constant current conditions (15 mA) at room temperature for 1.7 h. After the reaction is complete, triethylamine (3 mL) was added to quench the reaction. Then the reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic phase was concentrated in vacuo. The residue was purified by column chromatography on silica gel to afford the desired product **3** (Table S2).

10. HRMS data of Iminium ion 58



11. Cyclic voltammetric experiments




Figure S3. Cyclic voltammograms of substrates in 10 mL DMF-THF cosolvent (0.1 M ⁿBu₄NBF₄, DMF/THF = 1/1), using a glassy carbon as working electrode, Pt wire as counter and Ag/AgCl as reference electrodes, scan rate: 150 mV/s; **Blank:** no substrate; **Blank + ZnCl₂:** 1 M ZnCl₂ in THF (200 μL); **Blank + ZnCl₂ + BnBr:** 1 M ZnCl₂ in THF (200 μL), 1-(bromomethyl)-2-methylbenzene (300 μmol); **Blank + BnBr:** 1-(bromomethyl)-2-methylbenzene (300 μmol).





Figure S4. Cyclic voltammograms of substrates in 10 mL DMF-THF cosolvent (0.1 M ⁿBu₄NBF₄, DMF/THF = 1/1), using a glassy carbon as working electrode, Pt wire as counter and Ag/AgCl as reference electrodes, scan rate: 100 mV/s; **Blank:** no substrate; **ⁿBu₄NI:** ⁿBu₄NI (200 μmol); **1:** amine **1** (200 μmol)


12. Characterization data for products

1-(2-methylbenzyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (3)




Target compound was obtained according to general procedure A giving pure product (73.3 mg, 78% yield, FE = 49%) or general procedure B giving pure product (70.5 mg, 75% yield, FE = 39%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.13 (d, J = 7.8 Hz, 2H), 7.08–7.03 (m, 2H), 7.02–6.95 (m, 4H), 6.92 (s, 1H), 6.76 (s, 2H), 6.65 (t, J = 7.3 Hz, 1H), 6.56 (d, J = 7.7 Hz, 1H), 4.81 (t, J = 7.0 Hz, 1H), 3.65 (p, J = 6.0 Hz, 1H), 3.50 (dt, J = 12.1, 6.0 Hz, 1H), 3.14 (s, 1H), 3.02 (dd, J = 13.6, 7.6 Hz, 1H), 2.95 (dt, J = 14.0, 6.0 Hz, 1H), 2.75 (d, J = 16.2 Hz, 1H), 1.90 (s, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 148.3, 136.5, 136.1, 135.8, 133.9, 129.5, 129.08, 128.2, 127.1, 126.4, 125.6, 125.3, 124.8, 124.5, 116.4, 112.8, 60.3, 41.1, 37.7, 26.3, 18.2. HRMS (ESI) m/z : $[\text{M} + \text{K}]^+$ Calcd for $\text{C}_{23}\text{H}_{23}\text{KN}$: 352.1468; Found: 352.1455.

1-(2-methylbenzyl)-2-(p-tolyl)-1,2,3,4-tetrahydroisoquinoline (4)




Target compound was obtained according to general procedure A giving pure product (78.5 mg, 80% yield, FE = 50%) or general procedure B giving pure product (77.5 mg, 79% yield, FE = 41%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.08 – 7.02 (m, 2H), 7.02 – 6.99 (m, 2H), 6.98 (d, J = 4.6 Hz, 2H), 6.94 (d, J = 8.3 Hz, 2H), 6.91 (t, J = 7.2 Hz, 1H), 6.66 (d, J = 8.1 Hz, 2H), 6.55 (d, J = 7.6 Hz, 1H), 4.76 (t, J = 6.9 Hz, 1H), 3.49 (dt, J = 12.0, 5.6 Hz, 1H), 3.11 (dd, J = 13.7, 6.3 Hz, 1H), 2.99 (dd, J = 13.5, 7.5 Hz, 1H), 2.94 (dt, J = 14.8, 7.0 Hz, 1H), 2.16 (s, 3H), 1.92 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 146.5, 136.7, 136.4, 135.8, 134.0, 129.5, 129.0, 128.7, 127.2, 126.4, 125.8, 125.5, 125.2, 124.7, 124.4, 113.4, 60.4, 41.1, 37.7, 26.2, 19.2, 18.3. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{26}\text{N}$: 328.2065; Found: 328.2058.

2-(4-methoxyphenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (5)



Target compound was obtained according to general procedure A giving pure product (74.1 mg, 72% yield, FE = 45%) or general procedure B giving pure product (72.1 mg, 70% yield, FE = 37%), purification by flash chromatography on silica gel (PE : EA = 20 : 1); colorless liquid; R_f : 0.5 (PE : EA = 10 : 1). ^1H NMR (600 MHz, CDCl_3) δ 7.06 (t, J = 7.2 Hz, 1H), 7.04 (d, J = 3.1 Hz, 1H), 7.01 (td, J = 7.7, 6.9, 2.7 Hz, 3H), 6.96 (d, J = 6.7 Hz, 1H), 6.91 (t, J = 7.2 Hz, 1H), 6.72 (s, 4H), 6.53 (d, J = 7.7 Hz, 1H), 4.67 (t, J = 6.9 Hz, 1H), 3.67 (s, 3H), 3.62 (dq, J = 9.4, 4.7 Hz, 1H), 3.47 (dt, J = 12.4, 5.2 Hz, 1H), 3.08 (dd, J = 13.6, 6.4 Hz, 1H), 2.99 – 2.91 (m, 2H), 2.69 (dt, J = 16.1, 4.6 Hz, 1H), 1.94 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 151.6, 143.4, 136.9, 136.6, 135.8, 133.8, 129.6, 129.1, 127.5, 126.5, 125.5, 125.3, 124.7, 124.4, 115.9, 113.7, 61.0, 54.7, 41.5, 37.2, 26.1, 18.3. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{26}\text{NO}$: 344.2014; Found: 344.2011.


2-(4-(tert-butyl)phenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (6)



Target compound was obtained according to general procedure A giving pure product (84.2 mg, 76% yield, FE = 48%) or general procedure B giving pure product (79.8 mg, 72% yield, FE = 38%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.25 (d, J


= 8.8 Hz, 2H), 7.16 – 7.08 (m, 5H), 7.06 (d, $J = 5.2$ Hz, 1H), 6.98 (t, $J = 7.1$ Hz, 1H), 6.79 (d, $J = 8.3$ Hz, 2H), 6.62 (d, $J = 7.7$ Hz, 1H), 4.86 (t, $J = 7.0$ Hz, 1H), 3.74 (p, $J = 5.6$ Hz, 1H), 3.58 (dt, $J = 12.0$, 5.9 Hz, 1H), 3.23 (t, $J = 10.0$ Hz, 1H), 3.10 – 3.01 (m, 2H), 2.82 (d, $J = 15.1$ Hz, 1H), 1.99 (s, 3H), 1.28 (s, 9H). ^{13}C NMR (151 MHz, CDCl_3) δ 136.5, 135.8, 134.1, 129.6, 129.1, 127.2, 126.5, 125.5, 125.3, 124.9, 124.8, 124.5, 112.7, 60.6, 41.2, 38.0, 32.8, 30.5, 26.3, 18.3. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{27}\text{H}_{32}\text{N}$: 370.2535; Found: 370.2529.

2-(4-fluorophenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (7)




Target compound was obtained according to general procedure A giving pure product (79.5 mg, 80% yield, FE = 50%) or general procedure B giving pure product (76.5 mg, 77% yield, FE = 40%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.19 – 7.12 (m, 2H), 7.12 – 7.07 (m, 3H), 7.04 (dd, $J = 16.0$, 7.0 Hz, 2H), 6.91 (t, $J = 8.7$ Hz, 2H), 6.79 – 6.71 (m, 2H), 6.69 (d, $J = 7.6$ Hz, 1H), 4.79 (t, $J = 6.9$ Hz, 1H), 3.77 – 3.68 (m, 1H), 3.56 (dt, $J = 11.9$, 5.5 Hz, 1H), 3.18 (dd, $J = 13.6$, 6.4 Hz, 1H), 3.06 (ddd, $J = 36.5$, 14.4, 6.4 Hz, 2H), 2.89 (d, $J = 16.2$ Hz, 1H), 2.21 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.0 (d, $J_{\text{C-F}} = 236.6$ Hz), 145.3, 136.6, 136.3, 135.7, 133.7, 129.5, 129.1, 127.4, 126.4, 125.7, 125.4, 124.8, 124.6, 114.8 (d, $J = 6.8$ Hz), 114.5 (d, $J = 22.0$ Hz), 60.9, 41.5, 37.8, 26.1, 18.3. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{23}\text{NF}$: 354.1636; Found: 354.1648.

2-(4-chlorophenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (8)




Target compound was obtained according to general procedure A giving pure product (79.1 mg, 76% yield, FE = 48%) or general procedure B giving pure product (79.1 mg, 76% yield, FE = 40%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.08 (t, $J = 7.3$ Hz, 1H), 7.04 (d, $J = 6.7$ Hz, 3H), 7.03 – 6.99 (m, 2H), 6.98 (d, $J = 6.9$ Hz, 1H), 6.95 (t, $J = 7.2$ Hz, 2H), 6.64 – 6.59 (m, 3H), 4.75 (t, $J = 6.9$ Hz, 1H), 3.65 – 3.60 (m, 1H), 3.46 (dt, $J = 12.1$, 5.9 Hz, 1H), 3.11 (dd, $J = 13.7$, 6.5 Hz, 1H), 3.02 (dd, $J = 13.6$, 7.1 Hz, 1H), 2.95 – 2.89 (m, 1H), 2.72 (d, $J = 16.0$ Hz, 1H), 1.93 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 146.9, 136.4, 136.0, 135.7, 133.8, 129.5, 129.2, 128.0, 127.3, 126.4, 125.8, 125.5, 124.9, 124.8, 113.9, 60.4, 41.4, 37.9, 26.2, 18.3. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{23}\text{ClN}$: 348.1519; Found: 348.1512.

2-(4-bromophenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (9)




Target compound was obtained according to general procedure A giving pure product (91.5 mg, 78% yield, FE = 49%) or general procedure B giving pure product (92.7 mg, 79% yield, FE = 41%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.17 (d, $J = 8.6$ Hz, 2H), 7.07 (t, $J = 7.3$ Hz, 1H), 7.04 (d, $J = 7.6$ Hz, 1H), 7.03 – 6.85 (m, 5H), 6.63 (d, $J = 6.9$ Hz, 1H), 6.56 (d, $J = 8.4$ Hz, 2H), 4.74 (t, $J = 6.9$ Hz, 1H), 3.65 – 3.57 (m, 1H), 3.45 (dt, $J = 12.2$, 5.9 Hz, 1H), 3.10 (dd, $J = 13.7$, 6.6 Hz, 1H), 3.02 (dd, $J = 13.8$, 7.1 Hz, 1H), 2.92 (dt, $J = 13.7$, 6.6 Hz, 1H), 2.71 (d, $J = 16.0$ Hz, 1H), 1.92 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 147.4, 136.4, 136.0, 135.7, 133.8, 130.8, 129.5, 129.2, 127.3, 126.3, 125.8, 125.5, 124.9, 124.8, 114.2, 108.1, 60.3, 41.2, 37.9, 26.2, 26.2, 18.3. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{23}\text{BrN}$: 392.1014; Found: 392.1006.

1-(2-methylbenzyl)-2-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline (10)




Target compound was obtained according to general procedure A giving pure product (83.5 mg, 73% yield, FE = 46%) or general procedure B giving pure product (86.9 mg, 76% yield, FE = 40%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.6 (PE). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.32 (d, J = 8.6 Hz, 2H), 7.08 (t, J = 7.3 Hz, 1H), 7.05 (d, J = 6.1 Hz, 1H), 7.00 (t, J = 6.7 Hz, 2H), 6.97 (d, J = 6.9 Hz, 3H), 6.66 (t, J = 8.3 Hz, 3H), 4.85 (t, J = 6.9 Hz, 1H), 3.65 (ddd, J = 12.1, 7.0, 5.1 Hz, 1H), 3.49 (ddd, J = 12.3, 7.5, 5.1 Hz, 1H), 3.12 (dd, J = 13.7, 6.6 Hz, 1H), 3.05 (dd, J = 13.7, 7.1 Hz, 1H), 2.92 (ddd, J = 15.6, 6.9, 5.0 Hz, 1H), 2.79 – 2.71 (m, 1H), 1.90 (s, 3H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 150.29, 136.18, 135.70, 133.83, 129.45, 129.24, 126.35, 125.99, 125.65, 125.46 (q, J = 3.8 Hz), 125.0, 124.1 (d, J = 269.9 Hz), 123.2, 121.4, 117.2 (q, J = 32.8 Hz), 112.0, 110.9, 59.9, 41.3, 37.9, 26.4, 18.2. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{23}\text{F}_3\text{N}$: 382.1783; Found: 382.1776.

2-([1,1'-biphenyl]-4-yl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (11)




Target compound was obtained according to general procedure A giving pure product (82.9 mg, 71% yield, FE = 44%) or general procedure B giving pure product (91.1 mg, 78% yield, FE = 41%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.45 (d, J = 6.8 Hz, 2H), 7.38 (d, J = 8.7 Hz, 2H), 7.28 (t, J = 7.8 Hz, 2H), 7.17 – 7.12 (m, 1H), 7.05 (d, J = 7.8 Hz, 1H), 7.03 (s, 1H), 7.01 (d, J = 2.9 Hz, 3H), 6.97 (s, 1H), 6.92 (td, J = 7.3, 1.8 Hz, 1H), 6.77 (d, J = 8.7 Hz, 2H), 6.61 (d, J = 7.6 Hz, 1H), 4.85 (t, J = 6.9 Hz, 1H), 3.66 (ddd, J = 12.5, 7.7, 5.0 Hz, 1H), 3.52 (dt, J = 12.2, 6.0 Hz, 1H), 3.15 (dd, J = 13.7, 6.4 Hz, 1H), 3.04 (dd, J = 13.7, 7.4 Hz, 1H), 2.95 (ddd, J = 15.7, 7.7, 5.3 Hz, 1H), 2.73 (dt, J = 15.8, 5.8 Hz, 1H), 1.92 (s, 3H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 147.7, 140.1, 136.6, 136.2, 135.8, 134.0, 129.6, 129.2, 128.9, 127.6, 127.2, 126.8, 126.4, 125.7, 125.4, 125.2, 125.0, 124.9, 124.7, 112.7, 60.2, 41.2, 38.0, 26.4, 18.3. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{29}\text{H}_{28}\text{N}$: 390.2222; Found: 390.2216.

2-(3-(tert-butyl)phenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (12)




Target compound was obtained according to general procedure A giving pure product (61.9 mg, 56% yield, FE = 35%) or general procedure B giving pure product (58.6 mg, 53% yield, FE = 27%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.17 (d, J = 2.6 Hz, 1H), 7.16 (s, 1H), 7.04 (d, J = 7.0 Hz, 2H), 7.02 (d, J = 2.9 Hz, 3H), 7.00 – 6.97 (m, 1H), 6.90 (td, J = 7.2, 2.0 Hz, 1H), 6.71 (d, J = 8.2 Hz, 2H), 6.53 (d, J = 7.6 Hz, 1H), 4.77 (t, J = 7.0 Hz, 1H), 3.49 (dt, J = 12.0, 5.9 Hz, 1H), 2.99 (dd, J = 12.4, 6.5 Hz, 1H), 2.97 – 2.90 (m, 1H), 2.74 (d, J = 12.8 Hz, 1H), 1.90 (s, 3H), 1.20 (s, 9H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 146.3, 139.1, 136.8, 136.5, 135.8, 134.1, 129.6, 129.1, 127.2, 126.5, 125.5, 125.3, 124.9, 124.8, 124.5, 112.7, 60.5, 41.2, 38.1, 32.8, 30.5, 26.4, 18.3. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{26}\text{N}$: 370.2535; Found: 370.2530.

2-(3-fluorophenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (13)




Target compound was obtained according to general procedure A giving pure product (49.6 mg, 50% yield, FE = 31%) or general procedure B giving pure product (50.6 mg, 51% yield, FE = 27%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.11 – 7.02 (m, 3H), 7.02 – 6.99 (m, 2H), 6.97 (d, J = 9.0 Hz, 2H), 6.94 (t, J = 7.5 Hz, 1H), 6.61 (d, J = 7.6 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 6.37 (d, J = 13.1 Hz, 1H), 6.30 (t, J = 8.2 Hz, 1H), 4.77 (t, J = 6.9 Hz, 1H), 3.60 (ddd, J = 12.2, 7.2, 5.0 Hz, 1H), 3.43 (ddd, J = 12.3, 7.3, 5.3 Hz, 1H), 3.11 (dd, J = 13.6, 6.4 Hz, 1H), 3.03 (dd, J = 13.6, 7.4 Hz, 1H), 2.91 (ddd, J = 15.8, 7.2, 5.2 Hz, 1H), 2.72 (ddd, J = 15.8, 7.2, 5.1 Hz, 1H), 1.89 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 164.2 (d, J = 242.1 Hz), 151.0 (d, J = 10.5 Hz), 137.30, 136.920, 136.800, 135.0, 130.5, 130.1 (d, J = 10.2 Hz), 130.1, 128.1, 127.4, 126.9, 126.5, 125.9, 125.8, 108.7 (d, J = 2.2 Hz), 103.5 (d, J = 21.7 Hz), 100.2 (d, J = 25.9 Hz), 61.3, 42.5, 38.9, 27.4, 19.3. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{23}\text{FN}$: 332.1815; Found: 332.1807.

2-(3-chlorophenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (14)




Target compound was obtained according to general procedure A giving pure product (51 mg, 49% yield, FE = 31%) or general procedure B giving pure product (54.1 mg, 52% yield, FE = 27%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.07 (t, J = 7.3 Hz, 1H), 7.04 (d, J = 7.5 Hz, 1H), 7.03 – 6.80 (m, 6H), 6.66 (s, 1H), 6.63 (d, J = 7.6 Hz, 1H), 6.57 (dd, J = 16.6, 8.1 Hz, 2H), 4.77 (t, J = 6.9 Hz, 1H), 3.65 – 3.56 (m, 1H), 3.47 – 3.39 (m, 1H), 3.11 (dd, J = 13.7, 6.5 Hz, 1H), 3.03 (dd, J = 13.6, 7.2 Hz, 1H), 2.95 – 2.86 (m, 1H), 2.77 – 2.68 (m, 1H), 1.92 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 136.3, 135.9, 135.7, 134.1, 133.9, 129.5, 129.2, 129.0, 127.2, 126.4, 125.9, 125.5, 124.9, 124.8, 115.9, 112.2, 110.4, 60.2, 41.3, 37.9, 26.3, 18.3. HRMS (ESI) m/z : $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{23}\text{H}_{22}\text{NaClN}$: 348.1519; Found: 348.1513.

2-(3-bromophenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (15)




Target compound was obtained according to general procedure A giving pure product (63.3 mg, 54% yield, FE = 33%) or general procedure B giving pure product (66.8 mg, 57% yield, FE = 30%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.10 – 7.06 (m, 1H), 7.05 (d, J = 6.7 Hz, 1H), 7.01 (t, J = 7.4 Hz, 2H), 6.98 (d, J = 7.1 Hz, 1H), 6.96 (d, J = 7.8 Hz, 2H), 6.93 (d, J = 8.3 Hz, 1H), 6.81 (s, 1H), 6.72 (d, J = 7.8 Hz, 1H), 6.63 (d, J = 7.6 Hz, 1H), 6.59 (d, J = 11.0 Hz, 1H), 4.77 (t, J = 6.9 Hz, 1H), 3.61 (ddd, J = 12.4, 7.4, 5.1 Hz, 1H), 3.44 (ddd, J = 12.3, 7.0, 5.3 Hz, 1H), 3.11 (dd, J = 13.7, 6.6 Hz, 1H), 3.02 (dd, J = 13.6, 7.2 Hz, 1H), 2.92 (ddd, J = 15.8, 7.5, 5.3 Hz, 1H), 2.74 (ddd, J = 15.9, 6.9, 5.0 Hz, 1H), 1.93 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 149.5, 136.3, 135.9, 135.7, 133.9, 129.5, 129.3, 129.2, 127.2, 126.4, 125.9, 125.6, 124.1, 124.8, 122.5, 118.8, 115.1, 110.7, 60.1, 41.3, 37.9, 26.4, 18.3. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{23}\text{BrN}$: 392.1014; Found: 392.1008.

1-(2-methylbenzyl)-2-(o-tolyl)-1,2,3,4-tetrahydroisoquinoline (16)




Target compound was obtained according to general procedure A giving pure product (76.6 mg, 78% yield, FE = 49%) or general procedure B giving pure product (70.7 mg, 72% yield, FE = 24%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.09 (d, J = 6.0 Hz, 1H), 7.05 (d, J = 4.4 Hz, 1H), 7.04 (d, J = 5.6 Hz, 1H), 7.01 (d, J = 8.3 Hz, 1H), 6.98 (t, J = 2.7 Hz, 2H), 6.97 (d, J = 3.8 Hz, 1H), 6.94 (dd, J = 7.9, 2.5 Hz, 1H), 6.91 (d, J = 7.6 Hz, 1H), 6.85 (t, J = 7.6 Hz, 1H), 6.75 (d, J = 7.8 Hz, 1H), 6.71 (d, J = 7.6 Hz, 1H), 4.35 (t, J = 7.2 Hz, 1H), 3.65 (td, J = 12.5, 4.1 Hz, 1H), 3.16 (dd, J = 13.4, 6.0 Hz, 1H), 3.06 (dd, J = 14.0, 8.0 Hz, 1H), 2.93 (dd, J = 14.0, 6.4 Hz, 1H), 2.80 (td, J = 11.5, 5.9 Hz, 1H), 2.57 (d, J = 16.5 Hz, 1H), 2.09 (s, 3H), 2.03 (s, 3H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 149.4, 138.0, 137.1, 135.4, 134.1, 132.5, 130.0, 129.6, 129.0, 128.1, 126.2, 125.3, 125.2, 125.0, 124.5, 124.5, 122.2, 121.7, 60.6, 42.1, 38.2, 25.2, 18.2, 17.0. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{26}\text{N}$: 328.2065; Found: 328.2051.

2-(2,4-dimethylphenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (17)




Target compound was obtained according to general procedure A giving pure product (87.0 mg, 85% yield, FE = 53%) or general procedure B giving pure product (83.9 mg, 82% yield, FE = 43%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.08 (td, J = 7.4, 1.4 Hz, 1H), 7.04 (d, J = 7.5 Hz, 1H), 7.00 (t, J = 7.4 Hz, 1H), 6.99 – 6.88 (m, 4H), 6.86 (s, 1H), 6.72 (t, J = 8.5 Hz, 2H), 6.63 (d, J = 8.1 Hz, 1H), 4.31 (t, J = 7.2 Hz, 1H), 3.66 – 3.57 (m, 1H), 3.11 (dd, J = 13.3, 5.9 Hz, 1H), 3.05 (dd, J = 14.1, 8.1 Hz, 1H), 2.91 (dd, J = 14.0, 6.2 Hz, 1H), 2.79 (ddd, J = 17.3, 11.7, 6.1 Hz, 1H), 2.15 (s, 3H), 2.04 (s, 6H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 147.0, 138.2, 137.2, 135.4, 134.2, 132.4, 131.5, 130.7, 129.6, 129.0, 128.0, 126.2, 125.7, 125.2, 124.9, 124.5, 124.5, 121.7, 60.7, 42.2, 38.3, 25.0, 19.6, 18.4, 16.9. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{25}\text{H}_{28}\text{N}$: 342.2222; Found: 342.2203.

2-mesityl-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (18)



Target compound was obtained according to general procedure A giving pure product (99.1 mg, 93% yield, FE = 58%) or general procedure B giving pure product (95.9 mg, 90% yield, FE = 47%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.08 (d, J = 7.5 Hz, 1H), 7.04 (t, J = 7.4 Hz, 1H), 6.96 (d, J = 7.2 Hz, 1H), 6.91 (d, J = 7.5 Hz, 2H), 6.85 (s, 1H), 6.81 (s, 1H), 6.75 (t, J = 7.5 Hz, 1H), 6.71 – 6.61 (m, 1H), 6.01 (d, J = 7.6 Hz, 1H), 4.27 (dd, J = 10.2, 4.3 Hz, 1H), 3.40 – 3.32 (m, 1H), 3.12 (td, J = 9.8, 3.1 Hz, 1H), 3.09 – 3.04 (m, 1H), 3.02 (dd, J = 13.1, 4.5 Hz, 1H), 2.82 – 2.72 (m, 2H), 2.32 (s, 3H), 2.21 (s, 3H), 2.01 (s, 3H), 1.61 (s, 3H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 144.2, 137.0, 136.5, 136.4, 135.9, 135.8, 135.1, 133.4, 129.6, 129.2, 128.9, 128.8, 127.1, 126.7, 125.0, 124.9, 124.4, 123.8, 62.5, 46.2, 41.4, 30.3, 19.8, 18.1, 18.0, 17.7. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{30}\text{N}$ 356.2378; Found: 356.2367.


5-bromo-2-(2,4-dimethylphenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (19)



Target compound was obtained according to general procedure A giving pure product (100.6 mg, 80% yield, FE = 50%) or general procedure B giving pure


product (94.3 mg, 75% yield, FE = 39%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.21 (s, 1H), 7.09 (d, J = 10.4 Hz, 1H), 6.98 (d, J = 7.1 Hz, 3H), 6.90 (d, J = 6.9 Hz, 1H), 6.88 (s, 1H), 6.74 (d, J = 9.6 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 6.49 (d, J = 8.2 Hz, 1H), 4.24 (t, J = 7.2 Hz, 1H), 3.63 – 3.51 (m, 1H), 3.10 (dd, J = 13.4, 5.9 Hz, 1H), 3.02 (dd, J = 13.9, 7.5 Hz, 1H), 2.86 (dd, J = 13.9, 6.8 Hz, 1H), 2.79 (ddd, J = 17.4, 11.3, 6.0 Hz, 1H), 2.55 (d, J = 16.9 Hz, 1H), 2.16 (s, 3H), 2.05 (s, 3H), 2.00 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 146.6, 137.1, 136.7, 136.6, 135.4, 132.4, 131.8, 130.8, 130.8, 129.6, 129.1, 127.9, 127.5, 125.7, 125.1, 124.6, 121.6, 118.9, 60.4, 41.9, 37.9, 25.2, 19.7, 18.3, 16.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{25}\text{H}_{27}\text{BrN}$ 420.1327; Found 420.1318.

6-bromo-2-(2,4-dimethylphenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (20)




Target compound was obtained according to general procedure A giving pure product (96.8 mg, 77% yield, FE = 48%) or general procedure B giving pure product (99.3 mg, 79% yield, FE = 41%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.37 (d, J = 7.9 Hz, 1H), 6.99 (d, J = 4.7 Hz, 3H), 6.90 (d, J = 6.8 Hz, 1H), 6.89 – 6.84 (m, 2H), 6.74 (d, J = 8.0 Hz, 1H), 6.60 (d, J = 6.8 Hz, 2H), 4.26 (t, J = 7.1 Hz, 1H), 3.63 (ddd, J = 13.1, 11.3, 4.6 Hz, 1H), 3.20 (dd, J = 13.5, 6.4 Hz, 1H), 3.05 (dd, J = 13.9, 7.5 Hz, 1H), 2.89 (dd, J = 13.9, 6.8 Hz, 1H), 2.72 (d, J = 16.3 Hz, 1H), 2.64 (ddd, J = 17.5, 11.3, 6.5 Hz, 1H), 2.16 (s, 3H), 2.06 (s, 3H), 2.00 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 146.5, 140.7, 136.7, 135.4, 133.7, 132.3, 131.7, 130.8, 129.6, 129.4, 129.1, 125.7, 125.6, 125.4, 125.1, 124.6, 124.5, 121.3, 60.8, 42.0, 37.7, 26.2, 19.7, 18.3, 16.9. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{25}\text{H}_{27}\text{BrN}$ 420.1327; Found 420.1319.

7-bromo-2-(2,4-dimethylphenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (21)



Target compound was obtained according to general procedure A giving pure product (99.3 mg, 79% yield, FE = 49%) or general procedure B giving pure product (104.4 mg, 83% yield, FE = 44%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.20 (d, J = 8.2 Hz, 1H), 7.00 (d, J = 6.7 Hz, 3H), 6.91 (d, J = 8.3 Hz, 2H), 6.87 (s, 1H), 6.78 (s, 1H), 6.72 (d, J = 10.3 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 4.24 (t, J = 7.3 Hz, 1H), 3.60 – 3.53 (m, 1H), 3.10 (dd, J = 13.4, 6.0 Hz, 1H), 3.03 (dd, J = 14.0, 8.0 Hz, 1H), 2.88 (dd, J = 13.9, 6.5 Hz, 1H), 2.70 (ddd, J = 17.4, 11.7, 6.1 Hz, 1H), 2.48 (d, J = 16.2 Hz, 1H), 2.15 (s, 3H), 2.03 (s, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 146.6, 140.3, 136.6, 135.3, 133.1, 132.4, 131.8, 130.8, 129.7, 129.5, 129.1, 129.1, 128.2, 125.7, 125.2, 124.6, 121.5, 117.9, 60.5, 42.0, 38.1, 24.6, 19.7, 18.3, 16.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{25}\text{H}_{27}\text{BrN}$ 420.1327; Found 420.1321.


2-(2,4-dimethylphenyl)-7-fluoro-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (22)



Target compound was obtained according to general procedure A giving pure product (83.0 mg, 77% yield, FE = 48%) or general procedure B giving pure product (86.2 mg, 80% yield, FE = 42%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 6.99 (q, J = 5.3, 4.2 Hz, 4H), 6.94 (d, J = 5.2 Hz, 1H), 6.86 (s, 1H), 6.79 (td, J = 8.4, 2.7 Hz, 1H), 6.71 (d, J = 8.0 Hz, 1H), 6.60 (d, J = 8.0 Hz, 1H), 6.39 (d, J = 9.6 Hz, 1H), 4.26 (t, J = 7.2 Hz, 1H), 3.57 (dd, J = 14.7, 10.4 Hz, 1H), 3.10 (dd, J = 13.8, 5.5 Hz, 1H), 3.04 (dd, J = 14.0, 8.0 Hz, 1H), 2.89 (dd, J = 14.0,


6.4 Hz, 1H), 2.75 – 2.67 (m, 1H), 2.49 (s, 1H), 2.15 (s, 3H), 2.04 (s, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 159.6 (d, *J* = 243.9 Hz), 146.7, 140.0 (d, *J* = 6.1 Hz), 136.8, 135.3, 132.4, 131.7, 130.8, 129.7 (d, *J* = 2.8 Hz), 129.5, 129.3 (d, *J* = 7.4 Hz), 129.1, 125.7, 125.2, 124.6, 121.6, 112.5 (d, *J* = 21.0 Hz), 112.3 (d, *J* = 21.3 Hz), 60.7, 42.3, 38.1, 24.3, 19.6, 18.3, 16.8. HRMS (ESI) *m/z*: [M + H]⁺ Calcd for C₂₅H₂₇N 360.2128; Found 360.2111.

7-chloro-2-(2,4-dimethylphenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (23)




Target compound was obtained according to general procedure A giving pure product (84.4 mg, 75% yield, FE = 47%) or general procedure B giving pure product (84.4 mg, 75% yield, FE = 40%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f: 0.4 (PE). ¹H NMR (600 MHz, CDCl₃) δ 7.06 (d, *J* = 8.1 Hz, 1H), 7.03 – 6.98 (m, 3H), 6.97 (d, *J* = 8.2 Hz, 1H), 6.92 (d, *J* = 6.6 Hz, 1H), 6.86 (s, 1H), 6.72 (d, *J* = 8.1 Hz, 1H), 6.64 (s, 1H), 6.59 (d, *J* = 8.0 Hz, 1H), 4.25 (t, *J* = 7.3 Hz, 1H), 3.57 (td, *J* = 12.5, 4.1 Hz, 1H), 3.10 (dd, *J* = 13.5, 6.0 Hz, 1H), 3.03 (dd, *J* = 14.0, 8.0 Hz, 1H), 2.88 (dd, *J* = 14.0, 6.5 Hz, 1H), 2.73 (ddd, *J* = 17.4, 11.6, 6.1 Hz, 1H), 2.51 (d, *J* = 13.7 Hz, 1H), 2.15 (s, 3H), 2.03 (s, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 146.6, 139.9, 136.7, 135.3, 132.6, 132.4, 131.8, 130.8, 129.9, 129.5, 129.3, 129.1, 126.1, 125.7, 125.4, 125.2, 124.6, 121.6, 60.5, 42.1, 38.1, 24.5, 19.6, 18.3, 16.8. HRMS (ESI) *m/z*: [M + H]⁺ Calcd for C₂₅H₂₇ClN 376.1832; Found 376.1824.

2-(2,4-dimethylphenyl)-7-methyl-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (24)




Target compound was obtained according to general procedure A giving pure product (82.1 mg, 77% yield, FE = 48%) or general procedure B giving pure product (77.8 mg, 73% yield, FE = 38%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f: 0.4 (PE). ¹H NMR (600 MHz, CDCl₃) δ 7.01 – 6.94 (m, 4H), 6.91 (q, *J* = 7.8 Hz, 2H), 6.85 (s, 1H), 6.70 (d, *J* = 10.3 Hz, 1H), 6.63 (d, *J* = 8.1 Hz, 1H), 6.51 (s, 1H), 4.29 – 4.23 (m, 1H), 3.63 – 3.53 (m, 1H), 3.13 – 3.00 (m, 2H), 2.89 (dd, *J* = 14.0, 6.1 Hz, 1H), 2.77 – 2.67 (m, 1H), 2.48 (d, *J* = 21.3 Hz, 1H), 2.15 (d, *J* = 10.7 Hz, 6H), 2.04 (d, *J* = 10.8 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 148.1, 138.9, 138.40, 136.4, 134.8, 133.4, 132.4, 132.1, 131.7, 130.6, 129.9, 128.9, 127.8, 127.0, 126.7, 125.9, 125.4, 122.8, 61.7, 43.4, 39.4, 25.7, 21.1, 20.7, 19.4, 17.9. HRMS (ESI) *m/z*: [M + H]⁺ Calcd for C₂₆H₃₀N 356.2378; Found 356.2378.

2-(2,4-dimethylphenyl)-6,7-dimethoxy-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (25)




Target compound was obtained according to general procedure A giving pure product (81.8 mg, 68% yield, FE = 43%) or general procedure B giving pure product (85.5 mg, 71% yield, FE = 37%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f: 0.4 (PE : EA = 10 : 1). ¹H NMR (600 MHz, CDCl₃) δ 6.98 (s, 3H), 6.91 (s, 2H), 6.78 (d, *J* = 7.9 Hz, 1H), 6.72 (d, *J* = 8.1 Hz, 1H), 6.53 (s, 1H), 5.89 (s, 1H), 4.21 (t, *J* = 7.3 Hz, 1H), 3.78 (s, 3H), 3.60 (t, *J* = 12.3 Hz, 1H), 3.46 (s, 3H), 3.13 (dd, *J* = 13.4, 5.8 Hz, 1H), 3.01 (dd, *J* = 13.5, 6.2 Hz, 1H), 2.91 (dd, *J* = 13.5, 8.0 Hz, 1H), 2.76 (ddd, *J* = 16.9, 11.4, 6.1 Hz, 1H), 2.52 (d, *J* = 16.0 Hz, 1H), 2.18 (s, 3H), 2.13 (s, 3H), 1.93 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 147.0, 146.5, 145.4, 137.2, 135.8, 132.3, 131.5, 130.8, 129.7, 129.5, 129.1, 125.8, 125.7, 125.0, 124.6, 121.6, 110.6, 109.5, 60.4, 54.8, 54.5, 42.5, 37.5, 25.5, 19.7, 18.3, 17.0. HRMS (ESI) *m/z*: [M + H]⁺ Calcd for C₂₇H₃₂NO₂ 402.2433; Found 402.2432.

1-(2-methylbenzyl)-2-(pyridin-2-yl)-1,2,3,4-tetrahydroisoquinoline (26)




Target compound was obtained according to general procedure A giving pure product (65.0 mg, 69% yield, FE = 43%) or general procedure B giving pure product (62.2 mg, 66% yield, FE = 35%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE : EA = 10 : 1). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 5.48 (t, J = 6.8 Hz, 1H), 3.79 (p, J = 6.3 Hz, 1H), 3.62 (dt, J = 11.9, 5.9 Hz, 1H), 3.20 (dd, J = 13.3, 6.1 Hz, 1H), 3.04 (dd, J = 13.3, 7.7 Hz, 1H), 2.90 (dt, J = 15.7, 5.9 Hz, 1H), 2.79 (ddd, J = 15.7, 7.9, 5.2 Hz, 1H), 1.99 (s, 3H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 156.9, 146.7, 136.5, 136.2, 135.9, 134.3, 129.9, 128.9, 127.0, 126.6, 125.7, 125.3, 124.7, 124.6, 110.8, 105.1, 56.7, 39.9, 38.2, 27.04, 18.2. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{22}\text{H}_{23}\text{N}_2$ 315.1861; Found 315.1859.

1-allyl-2-benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (27)⁵




Target compound was obtained according to general procedure A giving pure product (30.0 mg, 31% yield, FE = 19%) or general procedure B giving pure product (27.0 mg, 28% yield, FE = 15%), purification by flash chromatography on aluminum trioxide (PE); colorless liquid; R_f : 0.4 (PE : EA = 10 : 1). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.30 (d, J = 7.5 Hz, 2H), 7.24 (t, J = 7.5 Hz, 2H), 7.19 – 7.16 (m, 1H), 6.51 (s, 1H), 6.46 (s, 1H), 5.86 – 5.76 (m, 1H), 4.97 – 4.91 (m, 2H), 3.78 (s, 3H), 3.75 (s, 3H), 3.72 (s, 1H), 3.64 (d, J = 13.8 Hz, 1H), 3.58 (t, J = 6.5 Hz, 1H), 3.11 (ddd, J = 14.2, 9.5, 4.8 Hz, 1H), 2.76 (ddd, J = 15.7, 9.6, 5.7 Hz, 1H), 2.70 (dt, J = 13.4, 4.3 Hz, 1H), 2.52 (dt, J = 14.6, 7.0 Hz, 1H), 2.44 (dt, J = 16.2, 4.4 Hz, 1H), 2.41 – 2.35 (m, 1H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 147.5, 147.2, 139.7, 136.9, 130.1, 128.8, 128.2, 126.9, 126.6, 115.7, 111.6, 111.0, 60.7, 57.9, 56.0, 55.9, 43.7, 40.4, 24.7. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{26}\text{NO}_2$ 324.1964; Found 324.1963.

1-(2-methylbenzyl)-2-(pyridin-2-yl)-1,2,3,4-tetrahydroisoquinoline (28)⁵



Target compound was obtained according to general procedure A giving pure product (43.1 mg, 53% yield, FE = 33%) or general procedure B giving pure product (45.0 mg, 55% yield, FE = 29%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE : EA = 2:1). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 6.59 (s, 1H), 6.56 (s, 1H), 5.86-6.00 (m, 2H), 5.15-5.23 (m, 2H), 5.06-5.09 (m, 1H), 5.04 (t, J = 1.23 Hz, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 3.71 (t, J = 6.40 Hz, 1H), 3.28 (s, 1H), 3.26 (s, 1H), 3.18-3.25 (m, 1H), 2.79-2.91 (m, 2H), 2.52-2.63 (m, 2H), 2.41-2.48 (m, 1H). HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{24}\text{N}$ 274.1807; Found 274.1802.


1-benzyl-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (29)



Target compound was obtained according to general procedure A giving pure product (78.5 mg, 80% yield, FE = 50%) or general procedure B giving pure product (71.6 mg, 73% yield, FE = 38%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.14 – 7.02 (m, 6H), 6.99 (d, J = 7.4 Hz, 2H), 6.91 (d, J = 7.4 Hz, 1H), 6.86 (s, 1H), 6.72 (d, J = 10.3 Hz, 1H), 6.64 (d, J = 8.1 Hz, 1H), 4.42 (t, J = 7.0 Hz, 1H), 3.47 (t, J = 12.2 Hz, 1H), 3.08 (dd, J = 14.2, 8.0 Hz, 2H), 2.91 (dd, J = 14.1, 5.6 Hz, 1H), 2.74 (dd, J = 16.4, 11.0 Hz, 1H), 2.51 (d, J = 16.4 Hz, 1H), 2.15 (s, 3H), 1.99 (s, 3H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 146.9, 139.1, 138.3, 134.4, 132.5, 131.5, 130.8, 128.5, 128.1, 126.9, 126.2, 125.7, 125.1, 124.8, 124.6, 121.1, 61.5, 42.7, 41.6, 25.1, 19.7, 16.8. HRMS (ESI) m/z : $[\text{M} +$


H]⁺ Calcd for C₂₄H₂₆N 328.2065; Found 328.2058.

1-(4-(tert-butyl)benzyl)-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (30)




Target compound was obtained according to general procedure A giving pure product (92.0 mg, 80% yield, FE = 50%) or general procedure B giving pure product (86.2 mg, 75% yield, FE = 39%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f: 0.4 (PE). ¹H NMR (600 MHz, CDCl₃) δ 7.14 (d, *J* = 8.3 Hz, 2H), 7.08 (q, *J* = 7.3, 6.1 Hz, 2H), 7.03 (d, *J* = 6.3 Hz, 1H), 6.96 (d, *J* = 5.8 Hz, 2H), 6.94 (s, 1H), 6.61 (d, *J* = 8.1 Hz, 1H), 4.38 (d, *J* = 3.2 Hz, 1H), 3.49 (ddd, *J* = 13.3, 11.3, 4.0 Hz, 1H), 3.10 – 2.99 (m, 2H), 2.88 (dd, *J* = 14.2, 5.4 Hz, 1H), 2.73 (ddd, *J* = 16.8, 11.3, 5.8 Hz, 1H), 2.15 (s, 3H), 1.21 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 147.6, 147.1, 138.6, 136.1, 134.4, 132.5, 131.4, 130.7, 128.1, 128.0, 126.1, 125.6, 125.1, 124.6, 123.8, 121.7, 61.5, 42.4, 41.3, 33.3, 30.4, 24.9, 19.7, 16.7. HRMS (ESI) *m/z*: [M + H]⁺ Calcd for C₂₈H₃₄N 384.2691; Found 384.2688.

2-(2,4-dimethylphenyl)-1-(4-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (31)




Target compound was obtained according to general procedure A giving pure product (80.9 mg, 79% yield, FE = 79%) or general procedure B giving pure product (74.7 mg, 73% yield, FE = 73%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f: 0.4 (PE). ¹H NMR (600 MHz, CDCl₃) δ 7.08 (t, *J* = 7.7 Hz, 1H), 7.05 (t, *J* = 6.9 Hz, 1H), 7.02 (d, *J* = 7.4 Hz, 1H), 6.92 (d, *J* = 7.7 Hz, 2H), 6.90 (d, *J* = 7.2 Hz, 1H), 6.89 – 6.84 (m, 3H), 6.71 (d, *J* = 8.0 Hz, 1H), 6.64 (d, *J* = 8.1 Hz, 1H), 4.37 (t, *J* = 7.0 Hz, 1H), 3.47 (td, *J* = 12.6, 11.6, 4.1 Hz, 1H), 3.05 (dt, *J* = 14.0, 7.7 Hz, 2H), 2.86 (dd, *J* = 14.1, 5.6 Hz, 1H), 2.73 (ddd, *J* = 16.8, 11.2, 5.8 Hz, 1H), 2.50 (d, *J* = 16.3 Hz, 1H), 2.21 (s, 3H), 2.15 (s, 3H), 2.04 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 147.0, 138.4, 136.0, 134.4, 134.1, 132.4, 131.4, 130.7, 128.3, 128.0, 127.6, 126.2, 125.7, 125.1, 124.6, 121.6, 61.6, 42.7, 41.2, 25.1, 20.0, 19.7, 16.9. HRMS (ESI) *m/z*: [M + H]⁺ Calcd for C₂₅H₂₈NO 342.2222; Found 342.2221.

2-(2,4-dimethylphenyl)-1-(4-fluorobenzyl)-1,2,3,4-tetrahydroisoquinoline (32)




Target compound was obtained according to general procedure A giving pure product (75.6 mg, 73% yield, FE = 46%) or general procedure B giving pure product (81.8 mg, 79% yield, FE = 42%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f: 0.4 (PE). ¹H NMR (600 MHz, CDCl₃) δ 7.12 – 7.06 (m, 2H), 7.04 (d, *J* = 8.0 Hz, 1H), 6.92 (dd, *J* = 8.3, 5.6 Hz, 3H), 6.87 (s, 1H), 6.80 (t, *J* = 8.6 Hz, 2H), 6.72 (d, *J* = 10.3 Hz, 1H), 6.65 (d, *J* = 8.1 Hz, 1H), 4.40 (t, *J* = 6.9 Hz, 1H), 3.46 – 3.39 (m, 1H), 3.10 – 3.00 (m, 2H), 2.89 (dd, *J* = 14.2, 5.5 Hz, 1H), 2.78 – 2.68 (m, 1H), 2.51 (d, *J* = 16.4 Hz, 1H), 2.16 (s, 3H), 2.00 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 160.4 (d, *J* = 243.2 Hz), 146.8, 137.9, 134.7, 134.5, 132.4, 131.7, 130.8, 129.8 (d, *J* = 7.7 Hz), 128.1, 126.1, 125.7, 125.2, 124.7, 121.5, 113.6 (d, *J* = 20.9 Hz), 61.5, 43.0, 40.7, 25.1, 19.7, 16.8. HRMS (ESI) *m/z*: [M + H]⁺ Calcd for C₂₄H₂₅FN 346.1971; Found 346.1972.

1-(4-chlorobenzyl)-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (33)




Target compound was obtained according to general procedure A giving pure product (75.8 mg, 70% yield, FE = 44%) or general procedure B giving pure product (79.1 mg, 73% yield, FE = 38%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.14 – 7.06 (m, 4H), 7.03 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 7.9 Hz, 1H), 6.90 (d, J = 8.3 Hz, 2H), 6.87 (s, 1H), 6.72 (d, J = 8.1 Hz, 1H), 6.64 (d, J = 8.0 Hz, 1H), 4.40 (dd, J = 8.2, 5.4 Hz, 1H), 3.41 (ddd, J = 13.4, 10.8, 4.1 Hz, 1H), 3.03 (dd, J = 14.3, 7.7 Hz, 2H), 2.89 (dd, J = 14.1, 5.3 Hz, 1H), 2.75 – 2.67 (m, 1H), 2.50 (d, J = 12.8 Hz, 1H), 2.16 (s, 3H), 1.99 (s, 3H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 147.8, 138.9, 138.6, 135.5, 133.4, 132.7, 131.8, 131.6, 130.8, 129.1, 128.0, 126.7, 126.2, 125.7, 122.5, 62.3, 43.9, 41.9, 26.1, 20.6, 17.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{25}\text{ClN}$ 362.1676; Found 362.1660.

1-(4-bromobenzyl)-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (34)




Target compound was obtained according to general procedure A giving pure product (89.9 mg, 74% yield, FE = 46%) or general procedure B giving pure product (91.1 mg, 75% yield, FE = 39%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.22 (d, J = 8.4 Hz, 2H), 7.08 (td, J = 6.7, 6.1, 3.8 Hz, 2H), 7.02 (d, J = 5.5 Hz, 1H), 6.93 (d, J = 5.6 Hz, 1H), 6.86 (s, 1H), 6.83 (d, J = 8.0 Hz, 2H), 6.71 (d, J = 8.0 Hz, 1H), 6.63 (d, J = 8.1 Hz, 1H), 4.39 (dd, J = 8.1, 5.5 Hz, 1H), 3.43 – 3.36 (m, 1H), 3.06 – 2.97 (m, 2H), 2.86 (dd, J = 14.2, 5.3 Hz, 1H), 2.70 (ddd, J = 16.4, 10.8, 5.5 Hz, 1H), 2.49 (dt, J = 16.5, 3.6 Hz, 1H), 2.15 (s, 3H), 1.98 (s, 3H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 147.8, 139.1, 138.9, 135.6, 133.4, 132.7, 131.9, 131.2, 131.0, 129.2, 127.1, 126.8, 126.3, 125.8, 122.5, 119.6, 62.3, 44.0, 42.0, 26.1, 20.7, 17.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{24}\text{BrN}$ 406.1170; Found 406.1160.

2-(2,4-dimethylphenyl)-1-(4-iodobenzyl)-1,2,3,4-tetrahydroisoquinoline (35)



Target compound was obtained according to general procedure A giving pure product (99.2 mg, 73% yield, FE = 46%) or general procedure B giving pure product (81.6 mg, 60% yield, FE = 26%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.42 (d, J = 8.3 Hz, 2H), 7.09 (t, J = 5.9 Hz, 2H), 7.03 (d, J = 7.0 Hz, 1H), 6.94 (d, J = 6.1 Hz, 1H), 6.87 (s, 1H), 6.72 (d, J = 8.3 Hz, 3H), 6.63 (d, J = 8.1 Hz, 1H), 4.39 (dd, J = 8.2, 5.4 Hz, 1H), 3.40 (ddd, J = 13.2, 10.8, 4.1 Hz, 1H), 3.03 (d, J = 11.3 Hz, 1H), 3.01 – 2.94 (m, 1H), 2.85 (dd, J = 14.1, 5.3 Hz, 1H), 2.75 – 2.66 (m, 1H), 2.49 (d, J = 16.4 Hz, 1H), 2.15 (s, 3H), 1.99 (s, 3H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 146.7, 138.8, 137.8, 136.3, 135.9, 134.5, 132.4, 131.7, 130.8, 130.6, 128.1, 126.8, 126.1, 125.7, 125.2, 124.9, 124.7, 121.5, 89.9, 61.2, 42.9, 41.1, 25.1, 19.8, 19.7, 16.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{25}\text{IN}$ 454.1032; Found 454.1031.


4-((2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)benzotrile (36)



Target compound was obtained according to general procedure A giving pure product (42.3 mg, 40% yield, FE = 25%) or general procedure B giving pure product (74.0 mg, 70% yield, FE = 37%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE : EA = 10 : 1). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.40 (d, J = 8.3 Hz, 2H), 7.12 (t, J = 4.9 Hz, 2H), 7.07 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 9.1 Hz,


1H), 7.01 – 6.95 (m, 1H), 6.86 (s, 1H), 6.73 (d, $J = 8.3$ Hz, 1H), 6.64 (d, $J = 8.1$ Hz, 1H), 4.48 (dd, $J = 8.5, 5.1$ Hz, 1H), 3.43 – 3.36 (m, 1H), 3.12 (dd, $J = 14.2, 8.5$ Hz, 1H), 3.02 (td, $J = 14.0, 4.3$ Hz, 2H), 2.70 (ddd, $J = 16.1, 10.5, 5.4$ Hz, 1H), 2.50 (d, $J = 16.4$ Hz, 1H), 2.16 (s, 3H), 1.92 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 146.4, 144.8, 137.4, 134.6, 132.3, 132.0, 130.92, 130.7, 129.2, 128.3, 125.9, 125.8, 125.5, 124.9, 121.4, 118.1, 108.7, 61.0, 43.1, 41.7, 25.0, 19.7, 16.7. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{25}\text{H}_{25}\text{N}$ 353.2018; Found 353.2012.

2-(2,4-dimethylphenyl)-1-(4-nitrobenzyl)-1,2,3,4-tetrahydroisoquinoline (37)




Target compound was obtained according to general procedure A giving pure product (60.5mg, 54% yield, FE = 33%) or general procedure B giving pure product (70.5 mg, 63% yield, FE = 33%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE : EA = 10 : 1). ^1H NMR (600 MHz, CDCl_3) δ 7.97 (d, $J = 8.4$ Hz, 2H), 7.12 (d, $J = 9.1$ Hz, 4H), 7.09 – 7.03 (m, 1H), 7.02 – 6.95 (m, 1H), 6.87 (d, $J = 2.3$ Hz, 1H), 6.74 (d, $J = 10.3$ Hz, 1H), 6.66 (d, $J = 8.1$ Hz, 1H), 4.54 (t, $J = 6.7$ Hz, 1H), 3.40 (ddd, $J = 14.0, 10.4, 4.1$ Hz, 1H), 3.18 (dd, $J = 14.2, 8.4$ Hz, 1H), 3.06 (dd, $J = 14.1, 5.1$ Hz, 2H), 2.71 (ddd, $J = 16.0, 10.4, 5.3$ Hz, 1H), 2.53 (d, $J = 16.4$ Hz, 1H), 2.16 (s, 3H), 1.95 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 147.1, 146.4, 145.4, 137.3, 134.7, 132.3, 132.1, 130.9, 129.2, 128.3, 125.9, 125.9, 125.5, 125.0, 122.1, 121.4, 61.0, 43.3, 41.4, 25.1, 19.7, 16.7. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_2$ 373.1916; Found 373.1910.

2-(2,4-dimethylphenyl)-1-(2-fluorobenzyl)-1,2,3,4-tetrahydroisoquinoline (38)



Target compound was obtained according to general procedure A giving pure product (72.5 mg, 70% yield, FE = 44%) or general procedure B giving pure product (65.2 mg, 63% yield, FE = 33%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.11 (dd, $J = 5.7, 3.3$ Hz, 2H), 7.07 (t, $J = 8.5$ Hz, 1H), 7.06 – 7.01 (m, 3H), 6.93 – 6.84 (m, 2H), 6.81 (s, 1H), 6.66 (d, $J = 8.1$ Hz, 1H), 6.55 (d, $J = 8.1$ Hz, 1H), 4.39 (dd, $J = 9.8, 4.9$ Hz, 1H), 3.56 (ddd, $J = 13.7, 11.8, 3.9$ Hz, 1H), 3.15 – 3.03 (m, 2H), 2.97 (dd, $J = 14.2, 4.8$ Hz, 1H), 2.79 – 2.66 (m, 1H), 2.46 (d, $J = 18.5$ Hz, 1H), 2.12 (s, 3H), 1.94 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 161.4, 159.7, 147.0, 138.3, 134.5, 132.4, 131.5, 130.8, 130.8, 130.6, 128.1, 126.5, 126.5, 126.4, 126.3, 126.1, 125.6, 125.2, 124.8, 122.5, 122.5, 121.7, 114.0, 113.9, 60.7, 42.0, 35.3, 24.2, 19.6, 16.6. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{25}\text{NF}$ 346.1971; Found 346.1962.


2-(2,4-dimethylphenyl)-1-(3-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (39)



Target compound was obtained according to general procedure A giving pure product (76.8 mg, 75% yield, FE = 47%) or general procedure B giving pure product (71.7 mg, 70% yield, FE = 37%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.08 (p, $J = 7.3$ Hz, 2H), 7.04 (t, $J = 7.9$ Hz, 1H), 7.01 (t, $J = 7.5$ Hz, 1H), 6.92 (d, $J = 7.3$ Hz, 1H), 6.87 (d, $J = 10.0$ Hz, 2H), 6.80 (d, $J = 11.1$ Hz, 2H), 6.71 (d, $J = 8.1$ Hz, 1H), 6.63 (d, $J = 8.1$ Hz, 1H), 4.38 (t, $J = 6.7$ Hz, 1H), 3.49 (t, $J = 10.3$ Hz, 1H), 3.13 – 2.96 (m, 2H), 2.86 (dd, $J = 14.0, 5.5$ Hz, 1H), 2.73 (ddd, $J = 16.8, 11.1, 5.8$ Hz, 1H), 2.50 (d, $J = 16.4$ Hz, 1H), 2.18 (s, 3H), 2.15 (s, 3H), 2.03 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 148.2, 140.0, 139.4, 137.3, 135.4, 133.4, 132.5, 131.8, 130.4, 129.0, 127.8, 127.2, 126.7, 126.5, 126.1, 125.6, 122.6, 62.7, 43.7, 42.6, 26.1, 21.3, 20.7, 17.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$


HJ⁺ Calcd for C₂₅H₂₈N 342.2222; Found 342.2213.

1-(3,4-dimethylbenzyl)-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (40)




Target compound was obtained according to general procedure A giving pure product (82.1 mg, 77% yield, FE = 48%) or general procedure B giving pure product (79.9 mg, 75% yield, FE = 40%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f: 0.4 (PE). ¹H NMR (600 MHz, CDCl₃) δ 7.07 (t, J = 7.8 Hz, 2H), 7.03 (d, J = 8.1 Hz, 1H), 6.92 (d, J = 7.2 Hz, 1H), 6.87 (d, J = 7.8 Hz, 2H), 6.77 (s, 1H), 6.75 – 6.69 (m, 2H), 6.63 (d, J = 8.1 Hz, 1H), 4.35 (t, J = 6.9 Hz, 1H), 3.49 (td, J = 12.4, 10.9, 4.0 Hz, 1H), 3.08 (d, J = 12.9 Hz, 1H), 3.02 (dd, J = 14.0, 8.2 Hz, 1H), 2.82 (dd, J = 14.0, 5.4 Hz, 1H), 2.73 (ddd, J = 16.6, 11.2, 5.6 Hz, 1H), 2.50 (d, J = 16.4 Hz, 1H), 2.15 (s, 3H), 2.12 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 139.5, 137.5, 135.8, 135.4, 133.7, 133.4, 132.4, 131.7, 130.9, 129.2, 129.0, 127.3, 126.8, 126.7, 126.0, 125.6, 122.6, 62.7, 43.7, 42.3, 26.1, 20.6, 19.5, 19.2, 17.9. HRMS (ESI) *m/z*: [M + H]⁺ Calcd for C₂₆H₃₀NO 356.2378; Found 356.2370.

2-(2,4-dimethylphenyl)-1-(1-phenylethyl)-1,2,3,4-tetrahydroisoquinoline (41)




Target compound was obtained according to general procedure B giving pure product trace or general procedure B giving pure product (67.6 mg, 66% yield, FE = 35%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f: 0.4 (PE). ¹H NMR (600 MHz, CDCl₃) δ 7.15 – 7.08 (m, 5H), 6.98 – 6.91 (m, 4H), 6.87 (s, 1H), 6.74 (q, J = 8.3 Hz, 2H), 4.45 (d, J = 5.8 Hz, 1H), 3.18 (t, J = 6.7 Hz, 1H), 2.98 (ddd, J = 13.2, 8.7, 4.6 Hz, 1H), 2.74 (dt, J = 13.0, 5.0 Hz, 1H), 2.55 (dd, J = 9.0, 5.4 Hz, 1H), 2.49 (d, J = 16.2 Hz, 1H), 2.16 (s, 3H), 1.95 (s, 3H), 1.20 (d, J = 7.1 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 148.1, 147.7, 144.3, 144.1, 137.1, 136.8, 135.6, 134.5, 133.1, 132.0, 131.7, 131.2, 130.81, 130.70, 127.80, 127.76, 127.59, 127.12, 126.97, 126.88, 125.89, 125.84, 125.13, 125.08, 124.9, 124.7, 124.1, 123.6, 122.2, 121.6, 65.9, 65.8, 46.0, 45.1, 44.4, 42.8, 25.8, 24.3, 19.7, 19.6, 18.7, 17.4, 16.9, 16.6, 16.4. HRMS (ESI) *m/z*: [M + H]⁺ Calcd for C₂₅H₂₈NO 342.2222; Found 342.2217.

2-(2,4-dimethylphenyl)-1-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline (42)



Target compound was obtained according to general procedure A giving pure product (82.5 mg, 73% yield, FE = 46%) or general procedure B giving pure product (76.8 mg, 68% yield, FE = 36%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f: 0.4 (PE). ¹H NMR (600 MHz, CDCl₃) δ 7.67 (d, J = 7.6 Hz, 1H), 7.59 (t, J = 8.9 Hz, 2H), 7.41 (s, 1H), 7.34 – 7.26 (m, 2H), 7.13 – 7.07 (m, 2H), 7.03 (d, J = 7.7 Hz, 2H), 6.93 (d, J = 7.5 Hz, 1H), 6.82 (s, 1H), 6.73 – 6.64 (m, 2H), 4.50 (d, J = 7.1 Hz, 1H), 3.51 (ddd, J = 14.3, 11.0, 3.9 Hz, 1H), 3.23 (dd, J = 14.1, 8.0 Hz, 1H), 3.07 (dt, J = 14.1, 7.1 Hz, 2H), 2.73 (ddd, J = 16.6, 10.9, 5.6 Hz, 1H), 2.59 – 2.46 (m, 1H), 2.13 (s, 3H), 1.96 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 146.9, 138.2, 136.7, 134.5, 132.5, 132.4, 131.5, 131.0, 130.8, 128.1, 127.1, 126.9, 126.5, 126.4, 126.3, 126.2, 125.7, 125.1, 124.6, 124.6, 124.0, 121.5, 61.4, 42.9, 41.7, 25.2, 19.6, 16.8. HRMS (ESI) *m/z*: [M + H]⁺ Calcd for C₂₈H₂₈N 378.2222; Found 378.2207.


1-allyl-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (43)



Target compound was obtained according to general procedure A giving pure product (69.0 mg, 83% yield, FE = 52%) or general procedure B giving pure


product (68.2 mg, 82% yield, FE = 43%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.11 (d, $J = 7.4$ Hz, 2H), 7.10 – 7.06 (m, 1H), 7.03 (d, $J = 7.4$ Hz, 1H), 6.94 (s, 1H), 6.77 (d, $J = 8.1$ Hz, 1H), 6.71 (d, $J = 8.1$ Hz, 1H), 5.74 (td, $J = 17.1, 6.9$ Hz, 1H), 4.87 (d, $J = 10.2$ Hz, 1H), 4.85 (s, 1H), 4.29 (dd, $J = 7.8, 4.6$ Hz, 1H), 3.38 – 3.29 (m, 1H), 3.02 (d, $J = 13.2$ Hz, 1H), 2.78 – 2.65 (m, 1H), 2.60 (d, $J = 16.3$ Hz, 1H), 2.56 – 2.49 (m, 1H), 2.42 – 2.36 (m, 1H), 2.23 (s, 3H), 2.18 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 147.1, 138.1, 135.7, 134.6, 132.8, 131.7, 130.7, 128.0, 126.0, 125.8, 124.9, 124.7, 121.6, 114.7, 59.7, 44.0, 39.54, 25.9, 19.7, 16.9. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{24}\text{N}$ 278.1909; Found 278.1901.

2-(2,4-dimethylphenyl)-1-(2-methylallyl)-1,2,3,4-tetrahydroisoquinoline (44)




Target compound was obtained according to general procedure A giving pure product (68.1 mg, 78% yield, FE = 49%) or general procedure B giving pure product (62.9 mg, 72% yield, FE = 38%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.15 – 7.05 (m, 3H), 7.01 (d, $J = 8.6$ Hz, 1H), 6.91 (s, 1H), 6.71 (d, $J = 8.1$ Hz, 1H), 6.60 (d, $J = 8.1$ Hz, 1H), 4.68 (s, 1H), 4.60 (s, 1H), 4.35 – 4.26 (m, 1H), 3.44 – 3.34 (m, 1H), 3.05 (d, $J = 13.0$ Hz, 1H), 2.70 (t, $J = 16.8$ Hz, 1H), 2.54 (dd, $J = 14.4, 9.2$ Hz, 1H), 2.45 (d, $J = 16.5$ Hz, 1H), 2.33 (d, $J = 14.4$ Hz, 1H), 2.21 (s, 3H), 2.17 (s, 3H), 1.58 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 147.1, 142.9, 139.0, 134.4, 132.4, 131.4, 130.7, 128.1, 125.9, 125.7, 124.9, 124.7, 121.6, 111.2, 58.1, 44.3, 42.2, 24.5, 21.1, 19.7, 16.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{26}\text{N}$ 292.2065; Found 292.2059.

(E)-1-(3,8-dimethylnona-2,7-dien-1-yl)-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (45)



Target compound was obtained according to general procedure A giving pure product (42.5 mg, 38% yield, FE = 24%) or general procedure B giving pure product (35.8 mg, 32% yield, FE = 17%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). ^1H NMR (600 MHz, CDCl_3) δ 7.09 (d, $J = 10.2$ Hz, 3H), 7.03 (d, $J = 6.9$ Hz, 1H), 6.93 (s, 1H), 6.77 (d, $J = 8.1$ Hz, 1H), 6.71 (d, $J = 8.2$ Hz, 1H), 5.13 (s, 1H), 5.03 – 4.93 (m, 1H), 4.21 (s, 1H), 3.37 (s, 1H), 3.04 (s, 1H), 2.73 (s, 1H), 2.60 (d, $J = 14.6$ Hz, 1H), 2.44 (d, $J = 8.2$ Hz, 1H), 2.33 (s, 1H), 2.23 (s, 3H), 2.18 (s, 3H), 2.01 – 1.89 (m, 2H), 1.86 (d, $J = 7.9$ Hz, 2H), 1.66 (m, 3H), 1.58 (m, 3H), 1.47 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 132.7, 130.7, 130.2, 127.9, 126.0, 125.7, 124.9, 124.7, 123.5, 121.7, 60.0, 38.8, 38.4, 36.4, 33.7, 28.7, 25.9, 25.6, 25.5, 24.9, 24.6, 22.4, 21.4, 19.7, 17.0, 16.6, 15.2. HRMS (ESI) m/z : $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{27}\text{H}_{35}\text{NNa}$ 396.2667; Found 396.2672.


2-(2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)acetonitrile (46)



Target compound was obtained according to general procedure A giving pure product (33.9 mg, 41% yield, FE = 26%) or general procedure B giving pure product (29.0 mg, 35% yield, FE = 18%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE : EA = 10 : 1). ^1H NMR (600 MHz, CDCl_3) δ 7.18 – 7.16 (m, 2H), 7.14 (d, $J = 9.0$ Hz, 1H), 7.12 – 7.08 (m, 1H), 6.99 (s, 1H), 6.85 (dd, $J = 8.1, 2.1$ Hz, 1H), 6.79 (d, $J = 8.0$ Hz, 1H), 4.60 (t, $J = 5.7$ Hz, 1H), 3.28 (ddd, $J = 12.7, 8.1, 4.6$ Hz, 1H), 3.06 (dt, $J = 12.8, 5.1$ Hz, 1H), 2.79 (dtt, $J = 21.1, 13.0, 4.8$ Hz, 2H), 2.69 (dd, $J = 16.7, 6.2$ Hz, 1H), 2.62 (dd, $J = 16.8, 5.3$ Hz, 1H), 2.30 (s, 3H), 2.21 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 146.6, 135.8, 135.6, 134.9,


134.3, 132.2, 129.4, 127.3, 127.2, 126.5, 126.4, 122.5, 118.3, 57.7, 46.2, 27.8, 24.8, 20.8, 17.8. HRMS (ESI) m/z : $[M + H]^+$ Calcd for $C_{19}H_{21}N_2$ 277.1705; Found 277.1703.

2-(2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)-1-phenylethan-1-one (47)




Target compound was obtained according to general procedure A giving pure product (67 mg, 63% yield, FE = 39%) or general procedure B giving pure product (51.1 mg, 48% yield, FE = 25%), purification by flash chromatography on aluminum trioxide (PE : EA = 200 : 1); colorless liquid; R_f : 0.4 (PE : EA = 10 : 1). 1H NMR (600 MHz, $CDCl_3$) δ 7.75 – 7.69 (m, 2H), 7.41 (t, J = 7.4 Hz, 1H), 7.29 (t, J = 7.8 Hz, 2H), 7.08 (d, J = 2.9 Hz, 3H), 7.06 – 7.02 (m, 1H), 6.84 (d, J = 2.5 Hz, 1H), 6.70 – 6.62 (m, 2H), 5.05 (t, J = 6.2 Hz, 1H), 3.54 (dd, J = 15.7, 7.3 Hz, 1H), 3.46 – 3.36 (m, 1H), 3.05 (dt, J = 14.9, 4.7 Hz, 2H), 2.80 (ddd, J = 16.3, 10.7, 5.6 Hz, 1H), 2.61 (dt, J = 16.5, 3.6 Hz, 1H), 2.12 (s, 3H), 2.04 (s, 3H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 198.8, 147.3, 139.2, 137.6, 135.1, 133.5, 132.9, 132.8, 131.8, 129.2, 128.4, 128.1, 126.8, 126.8, 126.4, 126.1, 122.4, 57.5, 45.0, 44.5, 35.5, 26.9, 20.7, 17.8. HRMS (ESI) m/z : $[M + H]^+$ Calcd for $C_{25}H_{26}NO$ 356.2014; Found 356.2008.

1-isopropyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (50)⁶




Target compound was obtained according to general procedure C giving pure product (46.1 mg, 55% yield, FE = 15%) purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). 1H NMR (600 MHz, $CDCl_3$) δ 7.14 (t, J = 7.9 Hz, 2H), 7.09 (d, J = 6.9 Hz, 1H), 7.06 (d, J = 6.1 Hz, 2H), 7.03 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.1 Hz, 2H), 6.62 (d, J = 7.4 Hz, 1H), 4.31 (d, J = 8.1 Hz, 1H), 3.67 (p, J = 6.0 Hz, 1H), 3.40 (dt, J = 12.0, 7.0 Hz, 1H), 2.96 – 2.87 (m, 2H), 1.00 (d, J = 6.9 Hz, 3H), 0.87 (d, J = 6.7 Hz, 3H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 149.1, 136.8, 134.3, 128.1, 127.3, 127.2, 125.6, 124.3, 115.6, 112.4, 63.7, 42.1, 33.4, 26.4, 19.6, 19.1.

1-cyclohexyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (51)⁶



Target compound was obtained according to general procedure C giving pure product (59.9 mg, 68% yield, FE = 18%) purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE). 1H NMR (600 MHz, $CDCl_3$) δ 7.13 (d, J = 8.8 Hz, 2H), 7.10 – 7.01 (m, 3H), 6.99 (d, J = 8.2 Hz, 1H), 6.78 (d, J = 8.2 Hz, 2H), 6.59 (t, J = 7.2 Hz, 1H), 4.34 (d, J = 8.2 Hz, 1H), 3.65 (dt, J = 12.0, 6.1 Hz, 1H), 3.39 (ddd, J = 11.9, 7.8, 6.2 Hz, 1H), 3.00 – 2.86 (m, 2H), 1.89 (d, J = 14.1 Hz, 1H), 1.66 (t, J = 14.6 Hz, 4H), 1.59 – 1.50 (m, 1H), 1.14 – 0.88 (m, 5H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 149.1, 136.9, 134.3, 128.1, 127.3, 127.2, 125.5, 124.2, 115.4, 112.1, 62.8, 43.1, 42.0, 30.0, 29.7, 26.4, 25.7, 25.4, 25.4.


1-allyl-2-(2-bromoallyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (53)



Target compound was obtained according to general procedure A giving pure product (61.1 mg, 50% yield, FE = 26%), purification by flash chromatography on silica gel (PE); colorless liquid; R_f : 0.4 (PE : EA = 10 : 1). 1H NMR (600 MHz, $CDCl_3$) δ 6.48 (d, J = 14.0 Hz, 2H), 5.98 – 5.79 (m, 2H), 5.50 (s, 1H), 4.97 (d, J = 12.4 Hz, 1H), 4.95 – 4.88 (m, 1H), 3.77 (d, J = 6.9 Hz, 6H), 3.59 (t, J = 6.4 Hz, 1H), 3.34 (s, 2H), 3.16 (ddd, J = 13.2, 10.3, 7.3 Hz, 1H), 2.75 (ddt, J = 22.1, 15.9, 5.6 Hz, 2H), 2.51 – 2.42 (m, 2H), 2.36 (dddd, J = 14.6, 8.6, 4.0, 2.6 Hz, 1H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 146.6, 146.3, 135.7, 131.3,


128.7, 125.3, 116.7, 115.0, 110.7, 109.9, 61.1, 59.9, 55.0, 54.9, 42.8, 39.8, 23.6. HRMS (ESI) m/z : $[M + H]^+$ Calcd for $C_{17}H_{23}BrNO_2$ 352.0912; Found 352.0905.

9,10-dimethoxy-2,3-dimethylene-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoline (54)⁷



Target compound was obtained according to general procedure A giving pure product (12.5 mg, 45% yield), purification by flash chromatography on silica gel (PE : EA = 5 : 1); colorless liquid; R_f : 0.4 (PE : EA = 3 : 1). 1H NMR (600 MHz, $CDCl_3$) δ 6.67 (s, 1H), 6.58 (s, 1H), 5.15 (d, $J = 2.6$ Hz, 2H), 4.88 (d, $J = 2.4$ Hz, 1H), 4.83 (s, 1H), 3.85 (d, $J = 16.4$ Hz, 6H), 3.47 (d, $J = 12.7$ Hz, 1H), 3.35 (dd, $J = 11.9, 3.2$ Hz, 1H), 3.13 (d, $J = 12.7$ Hz, 1H), 3.07 (ddd, $J = 15.6, 10.2, 5.4$ Hz, 1H), 3.01 (ddd, $J = 11.4, 5.7, 2.9$ Hz, 1H), 2.86 (dd, $J = 14.0, 3.1$ Hz, 1H), 2.67 (dt, $J = 15.7, 3.6$ Hz, 1H), 2.53 (td, $J = 10.8, 4.1$ Hz, 1H), 2.35 (td, $J = 12.7, 11.3, 2.6$ Hz, 1H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 147.6, 147.3, 145.44, 144.1, 129.5, 126.7, 111.5, 109.7, 109.3, 108.6, 62.0, 61.9, 56.1, 55.8, 50.8, 40.1, 29.2.

1-ethyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (57)⁸





1H NMR (400 MHz, $CDCl_3$) δ 7.19 – 7.12 (m, 2H), 7.09 – 7.01 (m, 4H), 6.79 (d, $J = 8.3$ Hz, 2H), 6.63 (t, $J = 7.1$ Hz, 1H), 4.48 (t, $J = 7.0$ Hz, 1H), 3.57 – 3.45 (m, 2H), 2.93 (ddd, $J = 15.9, 7.9, 5.4$ Hz, 1H), 2.78 (dt, $J = 15.8, 5.6$ Hz, 1H), 1.89 (dq, $J = 14.3, 7.2$ Hz, 1H), 1.68 (dq, $J = 14.2, 7.2$ Hz, 1H), 0.92 (t, $J = 7.4$ Hz, 3H).

13. References



1. Y. Yu, W. Yang, F. Rominger, and A. S. K. Hashmi. *Angew. Chem. Int. Ed.* 2013, **52**, 7586-7589
2. E. Szymanska, K. Frydenvang, A. C. Sanz, D. S. Pickering, E. Frola, Z. Serafimoska, B. Nielsen, J. S. Kastrup, and T. N. Johansen. *J. Med. Chem.* 2011, **54**, 7289-7298.
3. J. Xuan, T.-T. Zeng, Z.-J. Feng, Q.-H. Deng, J.-R. Chen, L.-Q. Lu, W.-J. Xiao, and H. Alper. *Angew. Chem. Int. Ed.* 2015, **54**, 1625-1628.
4. J. F. Franz, W. B. Krausab, K. Zeitler. *Chem. Commun.*, 2015, **51**, 8280-8283.
5. S. Dhanasekaran, V. Bisai, R. A. Unhale, A. Suneja, V. K. Singh. *Org. Lett.* 2014, **16**, 6068-6071.
6. D. Schönbauer, C. Sambigiato, T. Noël, M. Schnürch, *Beilstein J. Org. Chem.* 2020, **16**, 809-817.
7. S. Husinec, V. Savic, M. Simic, V. Tesevic, D. Vidovic, *Tetrahedron Lett.* 2011, **52**, 2733-2736.
8. H. Tian, W. Xu, Y. Liu, and Q. Wang, *Chem. Commun.* 2019, **55**, 14813-14816.

14. The spectra of NMR





1-(2-methylbenzyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (3)





1-(2-methylbenzyl)-2-(p-tolyl)-1,2,3,4-tetrahydroisoquinoline (4)





2-(4-methoxyphenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (5)





2-(4-fluorophenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (7)





2-(4-chlorophenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (8)





2-(4-bromophenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (9)





1-(2-methylbenzyl)-2-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline (10)





2-(3-(tert-butyl)phenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (12)





2-(3-chlorophenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (14)





2-(3-bromophenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (15)





1-(2-methylbenzyl)-2-(o-tolyl)-1,2,3,4-tetrahydroisoquinoline (16)






2-(2,4-dimethylphenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (17)





2-mesityl-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (18)





5-bromo-2-(2,4-dimethylphenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (19)





6-bromo-2-(2,4-dimethylphenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (20)





2-(2,4-dimethylphenyl)-7-fluoro-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (22)







7-chloro-2-(2,4-dimethylphenyl)-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (23)





2-(2,4-dimethylphenyl)-7-methyl-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (24)





2-(2,4-dimethylphenyl)-6,7-dimethoxy-1-(2-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (25)





1-(2-methylbenzyl)-2-(pyridin-2-yl)-1,2,3,4-tetrahydroisoquinoline (26)






1-allyl-2-benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (27)





1-benzyl-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (29)





1-(4-(tert-butyl)benzyl)-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (30)





2-(2,4-dimethylphenyl)-1-(4-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (31)





2-(2,4-dimethylphenyl)-1-(4-fluorobenzyl)-1,2,3,4-tetrahydroisoquinoline (32)





1-(4-chlorobenzyl)-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (33)








1-(4-bromobenzyl)-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (34)





2-(2,4-dimethylphenyl)-1-(4-iodobenzyl)-1,2,3,4-tetrahydroisoquinoline (35)





4-((2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)benzonitrile (36)







2-(2,4-dimethylphenyl)-1-(4-nitrobenzyl)-1,2,3,4-tetrahydroisoquinoline (37)





2-(2,4-dimethylphenyl)-1-(2-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline (38)







2-(2,4-dimethylphenyl)-1-(3-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (39)





1-(3,4-dimethylbenzyl)-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (40)





2-(2,4-dimethylphenyl)-1-(1-phenylethyl)-1,2,3,4-tetrahydroisoquinoline (41, dr=1.63)







2-(2,4-dimethylphenyl)-1-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline (42)







1-allyl-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (43)





2-(2,4-dimethylphenyl)-1-(2-methylallyl)-1,2,3,4-tetrahydroisoquinoline (44)





(E)-1-(3,8-dimethylnona-2,7-dien-1-yl)-2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (45)





2-(2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)acetonitrile (46)





2-(2-(2,4-dimethylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)-1-phenylethan-1-one (47)







1-isopropyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (50)







1-cyclohexyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (51)



1-allyl-2-(2-bromoallyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (53)



9,10-dimethoxy-2,3-dimethylene-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoline (54)



1-ethyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (57)

